CoChat

ADAR1 and ADAR2 associate with the RNA exosome and modulate RNA stability

Open access

The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index; none of the 141 sources its claims cite is checked for support yet.

Abstract

The adenosine deaminase acting on RNA (ADAR) enzymes deaminate adenosine to inosine in double-stranded (ds)RNA. Mammals express two catalytically active enzymes: ADAR1, which is ubiquitously expressed and essential for innate immune homeostasis, and ADAR2, which is enriched in the brain and vascular system. Here, we investigate the ADAR2 interactome and uncover a shared interaction network with ADAR1, including multiple components of the RNA exosome complex, a multi-subunit RNase involved in RNA processing, turnover, and surveillance. The interactions between ADARs and RNA exosome components are nuclear, and resistance to RNase A treatment implies their close proximity. We validated these interactions by immunoprecipitation of both endogenous and epitope-tagged ADAR proteins in multiple cell lines and mapped the interaction interfaces to their dsRNA-binding domains. Exploiting an MS2–MCP tethering system, we show that recruitment of ADAR1 or ADAR2 to the 3′ UTR of a reporter transcript decreases its stability. This decrease in RNA levels was reversed when EXOSC3 was depleted, demonstrating that this destabilizing effect of ADARs on RNA is via the RNA exosome complex. Finally, knockdown of ADARs perturbs rRNA processing, a canonical function of the nuclear exosome, demonstrating a cellular consequence of disrupting ADAR–exosome interactions.

Overview

CoChat Summary

TL;DR

ADAR1 and ADAR2 share a nuclear interaction network with RNA exosome components, dependent on their dsRNA-binding domains. Tethering ADARs to a reporter 3′ UTR destabilizes RNA via the exosome, and ADAR depletion perturbs rRNA processing.

Key findings

  • ADAR2 affinity-purification mass spectrometry in 293 T-REx cells yielded 107 high-confidence interactors out of 601 detected proteins; after excluding 31 ribosomal proteins, 76 interactors were compared, with 61 shared with ADAR1 datasets and 15 unique to ADAR2. All nine core exosome components were detected, and EXOSC2, EXOSC3, EXOSC5, EXOSC8, and EXOSC10 passed high-confidence filtering.
  • Co-IP validated interactions between ADAR1p110, ADAR1p150, ADAR2 and EXOSC3, EXOSC8, EXOSC10, and hMTR4; endogenous reciprocal co-IPs were seen in HEK293T and HeLa cells, and PLA showed nuclear proximity. Interactions were RNase A-resistant but abolished by dsRNA-binding-domain mutations, with minimal interacting regions including dsRBDs plus nuclear localization signals.
  • MS2–MCP tethering of ADAR1p110 or ADAR2 to a luciferase reporter 3′ UTR reduced reporter mRNA and luciferase activity; EXOSC3 knockdown suppressed this decrease, whereas DIS3L2 knockdown did not. Catalytically inactive and dsRNA-binding-defective mutants reduced mRNA similarly to WT, indicating an editing-independent effect.
  • ADAR depletion in PaTu, HeLa, and A549 cells caused accumulation of 7S pre-rRNA and extended 5.8S forms, while steady-state 5.8S rRNA was unchanged. RiboMeth-seq showed most rRNA 2′-O-methylation sites were unaffected, but ADAR-depleted samples had broader MethScore fluctuations (ΔMethScore −0.25 to +0.23) than controls (−0.04 to +0.05), with a subset exceeding |ΔMethScore| > 0.10.

Methods

  • ADAR2 interactome: doxycycline-inducible Flp-In 293 T-REx cells expressing SHN-tagged ADAR2; Strep-tag affinity purification followed by label-free LC-MS/MS; high-confidence interactors defined with SAINT and CRAPome filtering; networks built with STRING and Cytoscape.
  • Interaction validation: co-IP of epitope-tagged and endogenous ADARs and exosome components in HEK293T, HeLa, and related cell lines; RNase A treatment; deletion and dsRBD-mutant mapping; immunofluorescence and proximity ligation assay in HeLa cells.
  • Functional assays: MS2–MCP tethering in HEK293T cells with a pmirGLO reporter, RT–qPCR and Dual-Glo luciferase assays, and siRNA knockdown of EXOSC3 or DIS3L2; pre-rRNA processing by northern blotting in PaTu, HeLa, and A549 cells; RiboMeth-seq for rRNA 2′-O-methylation.

Limitations

  • Stated: pre-rRNA processing effects were modest and cell-type-specific, interpreted as a contributory rather than essential ADAR role; site-specific rRNA methylation changes likely reflect indirect consequences of altered processing kinetics; the authors cannot exclude that spatial redistribution contributes to loss of interaction in dsRBD mutants; PLA cannot determine whether observed foci are phase-separated condensates.
  • Stated: endogenous co-IPs had difficulty detecting EXOSC3 and EXOSC8, possibly due to small protein size, antibody heavy/light-chain proximity, or lower ADAR-bound pools; ADAR1p150 was detected more weakly, consistent with lower basal abundance and/or nuclear bias.
  • Evident: the main ADAR2 interactome derives from overexpressed tagged ADAR2 in 293 T-REx cells; RNase A resistance together with dsRBD dependence suggests structured-RNA-bridged association rather than direct protein–protein contact, which the paper notes remains unresolved.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/nar/gkag381

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Graphical Abstract
Graphical Abstract CC BY-NC · PubMed Central
Figure 1. Cross-dataset support for the ADAR2 interactome and network context. (A) UpSet plot summarizing overlap of ADAR2 AP-MS HCIs (this study) with reference resources, including two databases (IntAct and BioGRID) and a proximity-labeling dataset (BioID). Bars show the number of proteins in each exact intersection (dot matrix below); mint-colored bars mark intersections that include A2 AP-MS, and light peach bars denote proteins unique to this study. Set sizes are shown as horizontal bars on the left of each plot. (B) UpSet plot summarizing overlap of ADAR2 AP-MS HCIs (this study) with published ADAR1 interactomes (p110 and p150 isoforms; DIA/DDA combined) and the database (union of IntAct + BioGRID). Bars show the number of proteins in each exact intersection (dot matrix below); blue bars mark intersections that include A2 AP-MS HCIs, and red bars denote proteins unique to ADAR2 AP-MS. Set sizes are shown as horizontal bars on the left of each plot. (C) STRING protein–protein interaction network of ADAR2 HCIs visualized in Cytoscape. Nodes are HCIs, and edges represent the STRING interaction combined score. Node size is proportional to the spectral count for each interactor, normalized to the ADAR2 spectral count. Node fill indicates colors from the UpSet encoding from panel (A): teal = previously described interactor, peach = novel in this study. Node outline colors correspond to the UpSet encoding from panel (B): blue = identified as ADAR1 interactor, red = not described as ADAR1 interactor.
Figure 1. Cross-dataset support for the ADAR2 interactome and network context. (A) UpSet plot summarizing overlap of ADAR2 AP-MS HCIs (this study) with reference resources, including two databases (IntAct and BioGRID) and a proximity-labeling dataset (BioID). Bars show the number of proteins in each exact intersection (dot matrix below); mint-colored bars mark intersections that include A2 AP-MS, and light peach bars denote proteins unique to this study. Set sizes are shown as horizontal bars on the left of each plot. (B) UpSet plot summarizing overlap of ADAR2 AP-MS HCIs (this study) with published ADAR1 interactomes (p110 and p150 isoforms; DIA/DDA combined) and the database (union of IntAct + BioGRID). Bars show the number of proteins in each exact intersection (dot matrix below); blue bars mark intersections that include A2 AP-MS HCIs, and red bars denote proteins unique to ADAR2 AP-MS. Set sizes are shown as horizontal bars on the left of each plot. (C) STRING protein–protein interaction network of ADAR2 HCIs visualized in Cytoscape. Nodes are HCIs, and edges represent the STRING interaction combined score. Node size is proportional to the spectral count for each interactor, normalized to the ADAR2 spectral count. Node fill indicates colors from the UpSet encoding from panel (A): teal = previously described interactor, peach = novel in this study. Node outline colors correspond to the UpSet encoding from panel (B): blue = identified as ADAR1 interactor, red = not described as ADAR1 interactor.CC BY-NC · PubMed Central
Figure 2. Proximal interactions between ADARs and exosome components depend on ADAR dsRNA-binding. (A) An interaction proximity validation with RNase A treatment. Left, heatmaps; right, representative immunoblots. Total lysates were treated with RNase A for 1 h at 4°C (+RNase A) or left untreated, then subjected to 1 h anti-HA co-IP. (B) ADAR dsRNA-binding requirement for interaction. As in panel (A), but with WT ADAR1/ADAR2 and dsRNA-binding mutants (Mut.). In both panels, doxycycline-inducible 293 T-REx cells expressing StrepII-HA-ADARs (A1p110, A1p150, and A2) or GFP-StrepII-HA (control) were used. Heatmap tiles show GFP-normalized enrichment of the bound fraction (value printed in the tile); numbers in parentheses indicate detection frequencies across replicates. Palettes: red tiles denote novel interactors; blue tiles denote previously reported ADAR interactors. Inputs = 1% of lysate; bound lanes contain one-half of the eluate. Blots were probed for exosome components and known ADAR partners; HA reports bait recovery (mouse or rabbit anti-HA, as indicated), and the predicted molecular weights (kDa) are shown in brackets. See Supplementary Fig. S2 for additional details.
Figure 2. Proximal interactions between ADARs and exosome components depend on ADAR dsRNA-binding. (A) An interaction proximity validation with RNase A treatment. Left, heatmaps; right, representative immunoblots. Total lysates were treated with RNase A for 1 h at 4°C (+RNase A) or left untreated, then subjected to 1 h anti-HA co-IP. (B) ADAR dsRNA-binding requirement for interaction. As in panel (A), but with WT ADAR1/ADAR2 and dsRNA-binding mutants (Mut.). In both panels, doxycycline-inducible 293 T-REx cells expressing StrepII-HA-ADARs (A1p110, A1p150, and A2) or GFP-StrepII-HA (control) were used. Heatmap tiles show GFP-normalized enrichment of the bound fraction (value printed in the tile); numbers in parentheses indicate detection frequencies across replicates. Palettes: red tiles denote novel interactors; blue tiles denote previously reported ADAR interactors. Inputs = 1% of lysate; bound lanes contain one-half of the eluate. Blots were probed for exosome components and known ADAR partners; HA reports bait recovery (mouse or rabbit anti-HA, as indicated), and the predicted molecular weights (kDa) are shown in brackets. See Supplementary Fig. S2 for additional details.CC BY-NC · PubMed Central
Figure 3. ADARs interact with RNA exosome components at the endogenous level. (A) Co-IP of endogenous ADARs. Lysates were co-IPed with anti-ADAR1 or anti-ADAR2 and probed for RNA-exosome subunits hMTR4, EXOSC10, EXOSC3, and EXOSC8 and known ADAR partners DHX9, ILF3, and hnRNPC. Left, quantitative heatmaps; right, representative immunoblots. (B) Reciprocal co-IP of RNA exosome components. Co-IPs with antibodies to hMTR4, EXOSC10, EXOSC9, and DHX9 were probed for ADAR1 and ADAR2. Heatmaps and blots are shown as in panel (A). Quantification and loading. Heatmaps report IgG-normalized intensities of the bound fraction (value in each tile); the fraction in parentheses indicates detection frequency across replicates; gray = not assayed. The color scale reflects enrichment, with red = novel interactors and blue = previously reported interactors. Immunoblots load inputs = 0.5% of lysate and bound = ½ of the eluate; a rabbit IgG isotype IP serves as a negative control for nonspecific binding. The predicted molecular weights (kDa) are shown in brackets. See Supplementary Fig. S3 for additional details.
Figure 3. ADARs interact with RNA exosome components at the endogenous level. (A) Co-IP of endogenous ADARs. Lysates were co-IPed with anti-ADAR1 or anti-ADAR2 and probed for RNA-exosome subunits hMTR4, EXOSC10, EXOSC3, and EXOSC8 and known ADAR partners DHX9, ILF3, and hnRNPC. Left, quantitative heatmaps; right, representative immunoblots. (B) Reciprocal co-IP of RNA exosome components. Co-IPs with antibodies to hMTR4, EXOSC10, EXOSC9, and DHX9 were probed for ADAR1 and ADAR2. Heatmaps and blots are shown as in panel (A). Quantification and loading. Heatmaps report IgG-normalized intensities of the bound fraction (value in each tile); the fraction in parentheses indicates detection frequency across replicates; gray = not assayed. The color scale reflects enrichment, with red = novel interactors and blue = previously reported interactors. Immunoblots load inputs = 0.5% of lysate and bound = ½ of the eluate; a rabbit IgG isotype IP serves as a negative control for nonspecific binding. The predicted molecular weights (kDa) are shown in brackets. See Supplementary Fig. S3 for additional details.CC BY-NC · PubMed Central
Figure 4. Nuclear proximity of ADAR proteins and RNA exosome components. (A) Top, schematic of the colocalization for ADAR1 and exosome with PLA. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo. HeLa cells were stained with ADAR1-specific and RNA-exosome-specific antibodies. Bottom, representative microcopy images of Duolink PLA in HeLa between endogenous ADAR1 protein and RNA exosome components, as shown in panel (A). Nuclei are stained with DAPI (blue) and positive interaction is represented with PLA foci (green). Individual channels are shown in grayscale for better visualization; scale bar, 10 µm. Negative controls included no primary antibody or the matched IgG. Additional microscopic images are provided in Supplementary Fig. S4A. (B) Quantification of panel (A): PLA puncta per nucleus (each dot = one nucleus). Counts were obtained in ImageJ (Particle Analysis). Statistics: Kruskal–Wallis followed by Mann–Whitney tests with Holm correction (****P < .0001). Biological replicates n = 3–4; >50 cells per condition. “CTRL” combines the two negative controls. (C) Top, schematic for the ADAR2 PLA. HeLa T-REx cells expressing StrepII–HA–ADAR2 were induced 24 h before PLA and stained with mouse anti-HA plus antibodies to exosome subunits. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo. As in panel (A), with tagged ADAR2 versus endogenous exosome components in HeLa T-REx cells. Representative images; scale and staining information as in panel (A). Further details are provided in Supplementary Fig. S4C.
Figure 4. Nuclear proximity of ADAR proteins and RNA exosome components. (A) Top, schematic of the colocalization for ADAR1 and exosome with PLA. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo. HeLa cells were stained with ADAR1-specific and RNA-exosome-specific antibodies. Bottom, representative microcopy images of Duolink PLA in HeLa between endogenous ADAR1 protein and RNA exosome components, as shown in panel (A). Nuclei are stained with DAPI (blue) and positive interaction is represented with PLA foci (green). Individual channels are shown in grayscale for better visualization; scale bar, 10 µm. Negative controls included no primary antibody or the matched IgG. Additional microscopic images are provided in Supplementary Fig. S4A. (B) Quantification of panel (A): PLA puncta per nucleus (each dot = one nucleus). Counts were obtained in ImageJ (Particle Analysis). Statistics: Kruskal–Wallis followed by Mann–Whitney tests with Holm correction (****P < .0001). Biological replicates n = 3–4; >50 cells per condition. “CTRL” combines the two negative controls. (C) Top, schematic for the ADAR2 PLA. HeLa T-REx cells expressing StrepII–HA–ADAR2 were induced 24 h before PLA and stained with mouse anti-HA plus antibodies to exosome subunits. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo. As in panel (A), with tagged ADAR2 versus endogenous exosome components in HeLa T-REx cells. Representative images; scale and staining information as in panel (A). Further details are provided in Supplementary Fig. S4C.CC BY-NC · PubMed Central
Figure 5. ADAR dsRBD domains are required for RNA exosome interaction. (A) Left, domain cartoons of the ADAR1 expressing plasmids used for co-IPs. Middle, heatmap summarizing co-IP signals for indicated preys (IB). Values are the mean signal normalized to the ADAR1p110-expressing plasmid and fractions in parentheses indicate contributing replicates (e.g. 2/3). Color gradient corresponds to the fold change (red-RNA exosome components and blue-known ADAR interactors). Right, representative cropped immunoblots of HA-tag co-IP from transiently transfected HEK293T showing inputs and anti-HA co-IPs probed with the indicated antibodies (IB); their predicted molecular weights (kDa) are shown in brackets an anti-HA blot confirms bait recovery. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo. (B) Left, domain cartoons of the ADAR2-expressing plasmids used for co-IP. Middle, heatmap as in panel (A), with values normalized to plasmid expressing full-length ADAR2. Replicate counts are shown in parentheses for each tile and color gradient as in panel (A). Right, representative cropped immunoblots of HA-tag co-IP from doxycycline-induced HEK293 T-REx stable cell lines showing inputs and anti-HA co-IPs probed with the indicated antibodies (IB); an anti-HA blot confirms bait recovery. Conserved domains for ADAR1 and ADAR2 are shown in different colors: ZDNA/RNA-binding domain (ZBD), dsRNA-binding domains I–III (dsRBDs), deaminase domain (DD), and nuclear localization signal (NLS) of ADAR1 are shown as two red lines overlapping dsRBD III, and NLS of ADAR2 is shown as two black lines at N-terminus; nuclear export signal (NES) found in ADAR1p150 is in gray. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo.
Figure 5. ADAR dsRBD domains are required for RNA exosome interaction. (A) Left, domain cartoons of the ADAR1 expressing plasmids used for co-IPs. Middle, heatmap summarizing co-IP signals for indicated preys (IB). Values are the mean signal normalized to the ADAR1p110-expressing plasmid and fractions in parentheses indicate contributing replicates (e.g. 2/3). Color gradient corresponds to the fold change (red-RNA exosome components and blue-known ADAR interactors). Right, representative cropped immunoblots of HA-tag co-IP from transiently transfected HEK293T showing inputs and anti-HA co-IPs probed with the indicated antibodies (IB); their predicted molecular weights (kDa) are shown in brackets an anti-HA blot confirms bait recovery. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo. (B) Left, domain cartoons of the ADAR2-expressing plasmids used for co-IP. Middle, heatmap as in panel (A), with values normalized to plasmid expressing full-length ADAR2. Replicate counts are shown in parentheses for each tile and color gradient as in panel (A). Right, representative cropped immunoblots of HA-tag co-IP from doxycycline-induced HEK293 T-REx stable cell lines showing inputs and anti-HA co-IPs probed with the indicated antibodies (IB); an anti-HA blot confirms bait recovery. Conserved domains for ADAR1 and ADAR2 are shown in different colors: ZDNA/RNA-binding domain (ZBD), dsRNA-binding domains I–III (dsRBDs), deaminase domain (DD), and nuclear localization signal (NLS) of ADAR1 are shown as two red lines overlapping dsRBD III, and NLS of ADAR2 is shown as two black lines at N-terminus; nuclear export signal (NES) found in ADAR1p150 is in gray. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo.CC BY-NC · PubMed Central
Figure 6. EXOSC3 knockdown prevents reporter mRNA decrease when ADARs are tethered via the MS2–MCP system. (A) Scheme depicting workflow. HEK293T cells were co-transfected with pmirGLO reporters encoding MS2 stem-loops in the 3′ UTR and ADAR–MCP fusion constructs (or GFP–MCP). After incubation, luciferase reporter mRNA levels were measured with RT–qPCR and luciferase activity with the Dual-Glo® luciferase assay. Firefly signals were normalized to Renilla and then to the appropriate GFP control condition. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo. (B) ADAR1–MCP tethering assay. Left, domain cartoons of ADAR1 expressing plasmids. Middle, RT–qPCR fold change relative to GFP–MCP (dashed line = 1). Right, Dual-Glo activity relative to GFP–MCP (dashed line = 1). For each plasmid, Firefly/Renilla was computed per replicate and normalized to the GFP–MCP mean of that experiment. Bars show mean ± SD with jittered points (n = 4–6 independent replicates). Statistics: Welch’s ANOVA with Games–Howell post-hoc tests versus GFP–MCP; P < .05 (*), P < .01 (**), P < .001 (***), ns = not significant. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo. (C) ADAR2–MCP tethering. As in panel (B), but with ADAR2 deletion-expressing plasmids fused to MCP. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo. (D) HEK293T cells were transfected with CTRL, EXOSC3, or DIS3L2 siRNAs. After 30 h of siRNA transfection, cells were co-transfected with ADAR1/ADAR2–/GFP–MCP plus pmirGLO; analyses were performed at 48 h. Left, immunoblots showing target depletion and MCP-fusion expression; their predicted molecular weights (kDa) are shown in brackets. Right, Luciferase mRNA (qPCR) normalized to Renilla and expressed as fold change relative to CTRL (dashed line = 1). Bars represent mean ± SD from n = 3 biological replicates with individual points overlaid. Statistics: one-way ANOVA with Dunnett’s tests versus CTRL; P < .05 (*), P < .01 (**), ns = not significant.
Figure 6. EXOSC3 knockdown prevents reporter mRNA decrease when ADARs are tethered via the MS2–MCP system. (A) Scheme depicting workflow. HEK293T cells were co-transfected with pmirGLO reporters encoding MS2 stem-loops in the 3′ UTR and ADAR–MCP fusion constructs (or GFP–MCP). After incubation, luciferase reporter mRNA levels were measured with RT–qPCR and luciferase activity with the Dual-Glo® luciferase assay. Firefly signals were normalized to Renilla and then to the appropriate GFP control condition. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo. (B) ADAR1–MCP tethering assay. Left, domain cartoons of ADAR1 expressing plasmids. Middle, RT–qPCR fold change relative to GFP–MCP (dashed line = 1). Right, Dual-Glo activity relative to GFP–MCP (dashed line = 1). For each plasmid, Firefly/Renilla was computed per replicate and normalized to the GFP–MCP mean of that experiment. Bars show mean ± SD with jittered points (n = 4–6 independent replicates). Statistics: Welch’s ANOVA with Games–Howell post-hoc tests versus GFP–MCP; P < .05 (*), P < .01 (**), P < .001 (***), ns = not significant. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo. (C) ADAR2–MCP tethering. As in panel (B), but with ADAR2 deletion-expressing plasmids fused to MCP. Created in BioRender. O’Connell, M. (2026) https://BioRender.com/qnquldo. (D) HEK293T cells were transfected with CTRL, EXOSC3, or DIS3L2 siRNAs. After 30 h of siRNA transfection, cells were co-transfected with ADAR1/ADAR2–/GFP–MCP plus pmirGLO; analyses were performed at 48 h. Left, immunoblots showing target depletion and MCP-fusion expression; their predicted molecular weights (kDa) are shown in brackets. Right, Luciferase mRNA (qPCR) normalized to Renilla and expressed as fold change relative to CTRL (dashed line = 1). Bars represent mean ± SD from n = 3 biological replicates with individual points overlaid. Statistics: one-way ANOVA with Dunnett’s tests versus CTRL; P < .05 (*), P < .01 (**), ns = not significant.CC BY-NC · PubMed Central
Figure 7. ADARs contribute to efficient 3′-end maturation of 5.8S rRNA. (A) Processing in ITS2. Major processing steps are indicated. The RNA exosome is depicted as a Pac-Man symbol. The probe used in panel (A) (LD2079) is shown. (B) northern blot analysis (denaturing acrylamide gels). Ethidium-stained gels revealed the two forms of 5.8S rRNA (short and long, differing by a 7–8 nt 5′ extension) as well as the 5S rRNA, confirming equal loading across samples. Silencing was performed for 2 days with 30 nM siRNAs targeting ADAR1, ADAR2, or scrambled siRNA. (C) Quantification of 7S pre-rRNA. Levels of the 7S precursor (a Pol I transcript) were quantified and normalized to 5S rRNA (a Pol III transcript). (D) Selected rRNA sites showing notable MethScore changes across mock, scrambled siRNA (SCR), ADAR1-depleted (esiRNA and siRNA), and ADAR2-depleted cells; values correspond to the MethScore at the indicated 18S or 28S rRNA positions.
Figure 7. ADARs contribute to efficient 3′-end maturation of 5.8S rRNA. (A) Processing in ITS2. Major processing steps are indicated. The RNA exosome is depicted as a Pac-Man symbol. The probe used in panel (A) (LD2079) is shown. (B) northern blot analysis (denaturing acrylamide gels). Ethidium-stained gels revealed the two forms of 5.8S rRNA (short and long, differing by a 7–8 nt 5′ extension) as well as the 5S rRNA, confirming equal loading across samples. Silencing was performed for 2 days with 30 nM siRNAs targeting ADAR1, ADAR2, or scrambled siRNA. (C) Quantification of 7S pre-rRNA. Levels of the 7S precursor (a Pol I transcript) were quantified and normalized to 5S rRNA (a Pol III transcript). (D) Selected rRNA sites showing notable MethScore changes across mock, scrambled siRNA (SCR), ADAR1-depleted (esiRNA and siRNA), and ADAR2-depleted cells; values correspond to the MethScore at the indicated 18S or 28S rRNA positions.CC BY-NC · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 67 Not checked · 132 Own results and interpretations

84 more claims

Create a free account to see all 199 claims and to verify the 141 references still open.

See all claims — free account
  • It may state two separate claims as one. 72
  • Probably not a substantial claim. 61
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Cited by

Still being checked.

Metadata

Authors
Vukić, D., Du, Q., Cherian, A., Amoruso, D., Brožinová, K., Wacheul, L., Lacovich, V., Zorbas, C., Yadav, L., Sedmík, J., Keskitalo, S., Hajji, K., Stejskal, S., Varjosalo, M., Lafontaine, D. L. J., Keegan, L. P., & O’Connell, M. A.
Affiliations
  • Masaryk University (CZ)
  • Université Libre de Bruxelles (BE)
  • University of Helsinki (FI)
Corresponding author
O’Connell, Mary A
Venue
Nucleic Acids Research
Published
2026-04-23
Volume
54
Issue
8
Pages
gkag381
ISSN
  • 0305-1048 (ISSN-L)
  • 1362-4962
OpenAlex
W7155502859
Cited by
0
References
105
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • Nucleic Acids Research (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Helda - University of Helsinki Institutional Repository (publishedVersion)
Funders
  • Czech Science Foundation (GAČR, 21-27329X)
  • Belgian Fonds de la Recherche Scientifique (40007512)
  • Région Wallonne (SPW EER) Win4SpinOff (CA21154)
  • COST Action TRANSLACORE (CA21154)
  • European Joint Programme on Rare Diseases (EJP-RD): RiboEurope and DBAGeneCure (288475)
  • Marie Skłodowska-Curie Actions Doctoral Network (MSCA-DN) EURECA (288475)
  • Academy of Finland (288475)
  • Sigrid Jusélius Foundation
  • Finnish Cancer Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
Keywords
ADAR1, ADAR2, RNA exosome, RNA stability, RNA editing, dsRNA-binding domain, protein-protein interaction, EXOSC3, rRNA processing, 3' untranslated region, innate immunity, RNA turnover
MeSH terms
Adenosine Deaminase, Animals, Cell Line, Humans, Protein Binding, RNA, Double-Stranded, RNA-Binding Proteins, 3' Untranslated Regions, RNA Stability, Exosomes, HEK293 Cells, Exosome Multienzyme Ribonuclease Complex

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.